Positron Subsidiary Files Patent Applications for Proprietary Radiation Detection Technologies To Be Used in PET Scanners and Homeland Security Devices
Friday March 2, 4:01 pm ET
HOUSTON--(BUSINESS WIRE)--Positron Corporation (OTCBB: POSC - News; the Company), a developer and manufacturer of Positron Emission Tomography (PET) medical devices, announced today that through its subsidiary developed intellectual property in the field of solid state photo detection and its applications. The Company has four patents pending covering the design and construction of medical diagnostic molecular imaging scanners and radiation detection scanners for homeland security with its new class of solid state photodetectors. The compact, low-cost photodetectors have increased sensitivity that can detect a single quantum of light and may significantly reduce the cost of future PET scanners while improving spatial resolution and portability. Solid state photodetectors are the key component in the development of compact organ-specific PET scanners and effective radiation detection devices for monitoring of radiation proliferation by parties unfriendly to national security interests. The Company's research and development projects were conducted at facilities across North America with the participation of a team of collaborating scientists directed by Dr. Irving Weinberg. Dr. Weinberg is Chief Scientific Officer of the Positron research and development subsidiary.
The miniaturization afforded with this solid state photodetector technology is designed as the evolution of positron emission technologies that will enable the development of the next generation of efficient and economical full-body scanning devices, integrated PET/MRI scanners and the development of a single-use organ specific low-cost camera that can be disposed of after a single medical procedure.
The homeland security application is based on the ability to build a small transportable device using the compact solid state technology to detect very low levels of radiation emitted by illicit radioactive materials from a distance.
Dr. Irving Weinberg stated: "The solid state photodetectors will allow us to build radiation detection systems with high sensitivity. In new medical diagnostic nuclear imaging systems it will allow reduced patient radiation exposure because of lower radiopharmaceutical dosage, while in the homeland security application, a small radiation event can be detected from a substantial distance".
Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology. Positron Corporation incorporates patented and proprietary software and hardware technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. Positron's PET systems are in use at leading medical facilities throughout North America and in select International markets. Additional information may be found at www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (281) 492-7100.
Source: Positron Corporation
|Home | Molecular Imaging | Affiliates | Opportunity | Investment | Press | News | About | Contact | Sitemap|